Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 20

Sort by

Sort Order Select

Journal Articles

Antibiotic-induced loss of gut microbiome metabolic output correlates with clinical responses to CAR T-cell therapy

Blood blood.2024025366.

https://doi.org/10.1182/blood.2024025366

Published: 2024

Includes: Supplemental data

Journal Articles

A Multicenter Phase I Dose-Escalation Trial of a Novel Glutaminase Inhibitor Telaglenastat in Combination with Carfilzomib and Dexamethasone in Relapsed and Refractory Multiple Myeloma

Wilson I. Gonsalves, Natalia Neparidze, Jacob B. Allred, Shaji K Kumar, Joel M. Reid, Geoffrey Shapiro, Brian A. Costello, Richard Piekarz, Rachid C. Baz, Srinivas Devarakonda

Blood (2022) 140 (Supplement 1): 7315–7316.

https://doi.org/10.1182/blood-2022-164966

Published: 2022

Journal Articles

A Pilot Study of Azacitidine As Epigenetic Priming for Chemotherapy in Infants Less Than 1 Year of Age with KMT2A -Rearranged Acute Lymphoblastic Leukemia (ALL); Results from the Children's Oncology Group (COG) Trial AALL15P1

Erin Guest, John Kairalla, Meenakshi Devidas, Emily Hibbitts, Andrew J. Carroll, Nyla A. Heerema, Holly Kubaney, Amanda August, Melinda Pauly, Daniel Wechsler, Rodney R. Miles, Joel M. Reid, Cynthia Kihei, Lia Gore, Elizabeth A. Raetz, Stephen P. Hunger, Mignon L. Loh, Patrick A. Brown

Blood (2022) 140 (Supplement 1): 3256–3257.

https://doi.org/10.1182/blood-2022-167765

Published: 2022

Journal Articles

Bispecific CD33/CD123 Targeted Chimeric Antigen Receptor T Cells for the Treatment of Acute Myeloid Leukemia

Justin C. Boucher, Bishwas Shrestha, Paresh Vishwasrao, Mark B. Leick, Nhan Tu, Tayyebb Ghafoor, Kayla M. Reid, Kristen Spitler, Bin Yu, Marcela V. Maus, Marco L. Davila

Blood (2022) 140 (Supplement 1): 10275–10276.

https://doi.org/10.1182/blood-2022-163299

Published: 2022

Journal Articles

Phase I Trial of CD8-Depleted Human Leukocyte Antigen (HLA) Mismatched Unrelated Donor Lymphocyte Infusion (DLI) to Achieve Remissions in Myelodysplastic Syndrome (MDS) and Secondary Acute Myeloid Leukemia (sAML)

Blood (2022) 140 (Supplement 1): 886–888.

https://doi.org/10.1182/blood-2022-168175

Published: 2022

Journal Articles

A Novel IL2Rα-/- Model for CAR-T Toxicity in Acute Lymphoblastic Leukemia Recapitulates Cytokine Release Syndrome and Neutropenia

Payal Goala, Hiroshi Kotani, Zhang Yongliang, Kayla M. Reid, Justin C. Boucher, Constanza Savid-Frontera, Sae Bom Lee, Nolan Beatty, Michael D. Jain, Marco L. Davila

Blood (2022) 140 (Supplement 1): 1176–1177.

https://doi.org/10.1182/blood-2022-165562

Published: 2022

Journal Articles

Baseline Systemic Inflammatory Markers Interleukin 6 and Ferritin Are Associated with Toxicities and Progression-Free Survival in Multiple Myeloma Patients Treated with Idecabtagene Vicleucel

Blood (2022) 140 (Supplement 1): 12778–12780.

https://doi.org/10.1182/blood-2022-158080

Published: 2022

Journal Articles

Biphasic Neutrophil Recovery after CD19 CART in R/R LBCL Is Associated with Superior PFS/OS, Robust CAR T-Cell Expansion in Relation to Baseline Tumor Volume, and a Decrease of Systemic Inflammation over Time

Blood (2022) 140 (Supplement 1): 4549–4551.

https://doi.org/10.1182/blood-2022-167632

Published: 2022

Journal Articles

Relapsed Chronic Lymphocytic Leukemia Presenting with a Cardiac Mass: A Case Report

Amir Mahmoud, Ali Abdelhay, Mariam Mostafa, Soon Khai Low, Basant Eltaher, Simrat Gill, Zuhair Alam, Robin M. Reid

Blood (2022) 140 (Supplement 1): 12388–12389.

https://doi.org/10.1182/blood-2022-166350

Published: 2022

Journal Articles

Baseline CRP and Ferritin Identify Patients at High Risk of Poor Outcomes after Axicabtagene Ciloleucel Despite Corticosteroid Prophylaxis

Blood (2022) 140 (Supplement 1): 4678–4680.

https://doi.org/10.1182/blood-2022-171084

Published: 2022

Journal Articles

Whole-genome sequencing reveals complex genomic features underlying anti-CD19 CAR T-cell treatment failures in lymphoma

Michael D. Jain, Bachisio Ziccheddu, Caroline A. Coughlin, Rawan Faramand, Anthony J. Griswold, Kayla M. Reid, Meghan Menges, Yonghong Zhang, Ling Cen, Xuefeng Wang, Mohammad Hussaini, Ola Landgren, Marco L. Davila, Jonathan H. Schatz, Frederick L. Locke, Francesco Maura

Blood (2022) 140 (5): 491–503.

https://doi.org/10.1182/blood.2021015008

Published: 2022

Includes: Supplemental data

Journal Articles

Concurrent Monitoring of Peripheral Blood Circulating Tumor DNA and Circulating Tumor Cells in Relapsed/Refractory Follicular Lymphoma Patients Post Axicabtagene Ciloleucel, a Single Center Experience

Sameh Gaballa, Julio C. Chavez, Michael D. Jain, Meghan A Menges, Kayla M Reid, David Kaldas, Bijal D. Shah, Marco L. Davila, Frederick L. Locke

Blood (2021) 138 (Supplement 1): 2397.

https://doi.org/10.1182/blood-2021-149559

Published: 2021

Journal Articles

Genomic Drivers of Large B-Cell Lymphoma Resistance to CD19 CAR-T Therapy

Michael D. Jain, Bachisio Ziccheddu, Caroline A. Coughlin, Rawan Faramand, Anthony J. Griswold, Kayla M Reid, Ola Landgren, Frederick L. Locke, Francesco Maura, Marco L. Davila, Jonathan H. Schatz

Blood (2021) 138 (Supplement 1): 42.

https://doi.org/10.1182/blood-2021-148605

Published: 2021

Journal Articles

Outpatient Administration of High Dose BEAM Chemotherapy As Conditioning for Autologous Stem Cell Transplantation for Lymphoma Results in Fewer Infectious Complications and Improved Survival

Robin M. Reid, MD, Andrea Baran, MS, Paul M. Barr, MD, Michael W. Becker, MD, Steven H. Bernstein, MD, Jonathan W. Friedberg, MD, Jane L. Liesveld, MD, Gordon L. Phillips, MD, Lucy Wedow, FNP, Laurie A. Milner, MD

Blood (2014) 124 (21): 3984.

https://doi.org/10.1182/blood.V124.21.3984.3984

Published: 2014

Journal Articles

Reinduction Chemoimmunotherapy with Epratuzumab in Relapsed Acute Lymphoblastic Leukemia (ALL) in Children, Adolescents and Young Adults: Results From Children's Oncology Group (COG) Study ADVL04P2

Elizabeth A. Raetz, MD, Mitchell S. Cairo, MD, Michael J. Borowitz, MD, PhD, Xiaomin Lu, PhD, Meenakshi Devidas, PhD, Joel M. Reid, PhD, David M. Goldenberg, ScD, MD, William A Wegener, MD, PhD, James A. Whitlock, MD, Peter C. Adamson, MD, Stephen P Hunger, MD, William L. Carroll, MD

Blood (2011) 118 (21): 573.

https://doi.org/10.1182/blood.V118.21.573.573

Published: 2011

Journal Articles

Prevalence of pyruvate kinase deficiency in a northern European population in the north of England

Peter J. Carey, John Chandler, Alex Hendrick, Michael M. Reid, Peter William G. Saunders, Hazel Tinegate, Penelope R. Taylor, Nicholas West

Blood (2000) 96 (12): 4005–4006.

https://doi.org/10.1182/blood.V96.12.4005

Published: 2000

Journal Articles

Molecular basis of the Kell (K1) phenotype

S Lee, X Wu, M Reid, T Zelinski, C Redman

Blood (1995) 85 (4): 912–916.

https://doi.org/10.1182/blood.V85.4.912.bloodjournal854912

Published: 1995

Journal Articles

Topology of Kell blood group protein and the expression of multiple antigens by transfected cells

DC Russo, S Lee, M Reid, CM Redman

Blood (1994) 84 (10): 3518–3523.

https://doi.org/10.1182/blood.V84.10.3518.3518

Published: 1994

Journal Articles

A point mutation in the GYPC gene results in the expression of the blood group Ana antigen on glycophorin D but not on glycophorin C: further evidence that glycophorin D is a product of the GYPC gene

G Daniels, MJ King, ND Avent, G Khalid, M Reid, G Mallinson, J Symthe, B Cedergren

Blood (1993) 82 (10): 3198–3203.

https://doi.org/10.1182/blood.V82.10.3198.3198

Published: 1993

Journal Articles

Molecular analysis of glycophorin C deficiency in human erythrocytes

R Winardi, M Reid, J Conboy, N Mohandas

Blood (1993) 81 (10): 2799–2803.

https://doi.org/10.1182/blood.V81.10.2799.2799

Published: 1993

NARROW

Antibiotic-induced loss of gut microbiome metabolic output correlates with clinical responses to CAR T-cell therapy

A Multicenter Phase I Dose-Escalation Trial of a Novel Glutaminase Inhibitor Telaglenastat in Combination with Carfilzomib and Dexamethasone in Relapsed and Refractory Multiple Myeloma

A Pilot Study of Azacitidine As Epigenetic Priming for Chemotherapy in Infants Less Than 1 Year of Age with KMT2A -Rearranged Acute Lymphoblastic Leukemia (ALL); Results from the Children's Oncology Group (COG) Trial AALL15P1

Bispecific CD33/CD123 Targeted Chimeric Antigen Receptor T Cells for the Treatment of Acute Myeloid Leukemia

Phase I Trial of CD8-Depleted Human Leukocyte Antigen (HLA) Mismatched Unrelated Donor Lymphocyte Infusion (DLI) to Achieve Remissions in Myelodysplastic Syndrome (MDS) and Secondary Acute Myeloid Leukemia (sAML)

A Novel IL2Rα-/- Model for CAR-T Toxicity in Acute Lymphoblastic Leukemia Recapitulates Cytokine Release Syndrome and Neutropenia

Baseline Systemic Inflammatory Markers Interleukin 6 and Ferritin Are Associated with Toxicities and Progression-Free Survival in Multiple Myeloma Patients Treated with Idecabtagene Vicleucel

Biphasic Neutrophil Recovery after CD19 CART in R/R LBCL Is Associated with Superior PFS/OS, Robust CAR T-Cell Expansion in Relation to Baseline Tumor Volume, and a Decrease of Systemic Inflammation over Time

Relapsed Chronic Lymphocytic Leukemia Presenting with a Cardiac Mass: A Case Report

Baseline CRP and Ferritin Identify Patients at High Risk of Poor Outcomes after Axicabtagene Ciloleucel Despite Corticosteroid Prophylaxis

Whole-genome sequencing reveals complex genomic features underlying anti-CD19 CAR T-cell treatment failures in lymphoma

Concurrent Monitoring of Peripheral Blood Circulating Tumor DNA and Circulating Tumor Cells in Relapsed/Refractory Follicular Lymphoma Patients Post Axicabtagene Ciloleucel, a Single Center Experience

Genomic Drivers of Large B-Cell Lymphoma Resistance to CD19 CAR-T Therapy

Outpatient Administration of High Dose BEAM Chemotherapy As Conditioning for Autologous Stem Cell Transplantation for Lymphoma Results in Fewer Infectious Complications and Improved Survival

Reinduction Chemoimmunotherapy with Epratuzumab in Relapsed Acute Lymphoblastic Leukemia (ALL) in Children, Adolescents and Young Adults: Results From Children's Oncology Group (COG) Study ADVL04P2

Prevalence of pyruvate kinase deficiency in a northern European population in the north of England

Molecular basis of the Kell (K1) phenotype

Topology of Kell blood group protein and the expression of multiple antigens by transfected cells

A point mutation in the GYPC gene results in the expression of the blood group Ana antigen on glycophorin D but not on glycophorin C: further evidence that glycophorin D is a product of the GYPC gene

Molecular analysis of glycophorin C deficiency in human erythrocytes

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only